Tag - TLSA

Developments

Tiziana announces positive new biomarkers for nasal foralumab

Tiziana Life Sciences (NASDAQ: TLSA) has announced new biomarker data from a late-breaking poster presented by investigators from Brigham and Women’s Hospital, Boston, showing nasal foralumab downregulates cerebrospinal...

February 25, 2026

Developments

Tiziana doses first patient in Phase 2 trial of intranasal foralumab in AD

Tiziana Life Sciences (NASDAQ: TLSA) has announced that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease...

December 17, 2025

Developments

Tiziana Life Sciences submits IND for oral Foralumab

Tiziana Life Sciences (NASDAQ:TLSA, AIM:TILS) submitted an IND to the FDA for its enteric-coated capsules of Foralumab, an anti-CD3 monoclonal antibody. Foralumab, believed to induce an anti-inflammatory response by...

March 20, 2019

Tag - TLSA

Tiziana announces positive new biomarkers for nasal foralumab

Tiziana doses first patient in Phase 2 trial of intranasal foralumab in AD

Tiziana Life Sciences submits IND for oral Foralumab

Subscribe